S
Sofinnova Investments, Inc.
+ HoldingMANE
+7.79%
3M Return
$108.820
-5.909 (-5.43%)At close
Loading chart…
- High
- 114.250
- Open
- 114.190
- VWAP
- 109.86
- Volume
- 672.94K
- Mkt Cap
- —
- Low
- 106.510
- Amount
- 73.93M
- EV/EBITDA, TTM
- 0.00
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
AI analysis of Veradermics Inc (MANE)
BuyVeraDermics, Inc. (MANE) is a good buy right now due to its recent positive Phase 2 trial results for VDPHL01, which showed 88.9% of participants reporting improvement in hair loss. The stock is currently priced at $108.82, significantly below analyst targets of $160 from Citi and $170 from B. Riley, indicating substantial upside potential. Additionally, the stock has experienced a remarkable year-to-date change of +540.12%, reflecting strong investor interest and market confidence. However, the main risk is the negative net income trend, with a reported loss of $30,011,000 in Q1 2026, which investors should monitor closely.
Valuation Metrics
The current forward P/E ratio for Veradermics Inc (MANE) is 0.00, compared to its 5-year average forward P/E of .
Whales holding MANE
Events Timeline
News
8.509-03NewsfilterVeradermics to Participate in Upcoming Investor Conferences
- 9.008-11Newsfilter
VDPHL01 Shows Promising Results for Female Hair Loss Treatment
8.507-18NASDAQ.COMMultiple Biopharma Companies Receive FDA Approvals
- 9.007-17Newsfilter
Veradermics Presents Phase 2/3 Data for VDPHL01 in Hair Loss Treatment
2.007-16NASDAQ.COMBiotech Stocks Surge Amid Positive Developments
MANE FAQ — answered by Alphio AI
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL. It operates in the Healthcare sector.
VeraDermics, Inc. (MANE) is a good buy right now due to its recent positive Phase 2 trial results for VDPHL01, which showed 88.9% of participants reporting improvement in hair loss. The stock is currently priced at $108.82, significantly below analyst targets of $160 from Citi and $170 from B. Riley, indicating substantial upside potential. Additionally, the stock has experienced a remarkable year-to-date change of +540.12%, reflecting strong investor interest and market confidence. However, the main risk is the negative net income trend, with a reported loss of $30,011,000 in Q1 2026, which investors should monitor closely.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.